Last spring, drugmaker Amgen Inc. announced plans to buy  Microsoft Corp.’s Copilot AI assistant for 20,000 employees. It was ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Last spring, drugmaker Amgen Inc. announced plans to buy Microsoft Corp.’s Copilot AI assistant for 20,000 employees. It was ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Risk sentiment wavering: Before the potential ceasefire breach, the VIX index (a common gauge of investor fear) fell over 6.5 ...

Win Advisors Inc. recently acquired 3,241 shares of Amgen, investing roughly $1,010,000, as disclosed in their latest SEC ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...